Ameile qhov kev qhia thib plaub tau pom zoo rau kev lag luam, tsom mus rau kev kho mob tom qab phais rau EGFR mutation-positive non-small cell lung cancer

Thaum Lub Tsib Hlis 9, 2025, Hansoh Pharmaceutical tau tshaj tawm tias ib qho cim tshiab rau Ameile (almonertinib mesylate ntsiav tshuaj) tau raug pom zoo rau kev lag luam. Cov cim tshiab no yog rau kev kho mob adjuvant rau cov neeg laus uas muaj mob qog nqaij hlav tsis yog me me (NSCLC) uas lawv cov qog muaj epidermal growth factor receptor (EGFR) exon 19 deletion lossis exon 21 (L858R) mutations, thiab cov neeg uas tau raug phais qog. Tam sim no Ameile muaj plaub qhov cim pom zoo hauv Suav teb, tswj nws txoj haujlwm ua tus thawj coj ntawm cov neeg tsim khoom hauv tebchaws EGFR-TKIs tiam thib peb.

Qhov kev pom zoo no yog raws li kev tshawb fawb ARTS (HS-10296-302), uas yog kev sim tshuaj theem III uas tsis muaj kev kuaj mob, ob qho tib si, tswj tau, thiab ntau lub chaw kuaj mob. Cov txiaj ntsig ntawm kev tshawb fawb no tau nthuav tawm ua daim ntawv qhia txog kev kho mob ntawm Lub Rooj Sib Tham Txhua Xyoo ntawm American Association for Cancer Research (AACR) xyoo 2025.

Cov ntaub ntawv los ntawm kev tshawb fawb ARTS uas tau nthuav tawm ntawm Lub Rooj Sib Tham Txhua Xyoo 2025 AACR tau lees paub tias rau cov neeg mob uas tau phais tag nrho theem II-IIIB EGFR-mutant NSCLC, kev kho mob adjuvant nrog Ameile—thaum siv tau—tuaj yeem txhim kho kev ciaj sia tsis muaj kab mob (DFS). Tus nqi DFS 2-xyoo tau txog 90.2%, nrog HR ntawm 0.17, thiab qhov kev nyab xeeb tag nrho tau tswj tau. Qhov tseem ceeb, kev tshawb fawb tsuas yog sau npe rau cov neeg mob Suav xwb, qhia txog qhov ua tau zoo thiab kev nyab xeeb ntawm EGFR-TKI uas tsim hauv tebchaws hauv cov pej xeem Suav.

Txog Ameile

Raws li Tuam Tshoj thawj thawj tiam thib peb EGFR-TKI, Ameile (Aumolertinib Mesilate Tablets) muaj cov liposolubility zoo thiab ruaj khov, ua rau nws nkag mus rau hauv cov ntshav-lub hlwb zoo dua nrog qhov tshwm sim tsawg ntawm cov kev tsis zoo. Tam sim no, Ameile tau pom zoo rau plaub qhov cim qhia: kev kho mob kab thib ob ntawm cov neeg mob uas muaj NSCLC hauv zos lossis metastatic nrog T790M mutation, uas tau nce qib ntawm lossis tom qab kev kho mob EGFR-TKI; kev kho mob kab thib ib rau cov neeg mob laus uas muaj NSCLC hauv zos lossis metastatic uas lawv cov qog muaj EGFR exon 19 deletions lossis exon 21 (L858R) hloov pauv zoo; kev kho mob ntawm cov neeg mob uas muaj mob qog hauv zos, tsis tuaj yeem phais tau (Theem III) tsis yog mob qog nqaij hlav me me ("NSCLC") uas cov kab mob tsis tau nce qib tom qab kev kho mob platinum-based chemoradiotherapy uas cov qog muaj epidermal growth factor receptor ("EGFR") exon 19 deletions lossis exon 21 (L858R) hloov pauv; kev kho mob adjuvant rau cov neeg laus uas muaj mob qog nqaij hlav ntsws tsis yog me me (NSCLC) uas lawv cov qog muaj epidermal growth factor receptor (EGFR) exon 19 deletion lossis exon 21 (L858R) mutations, thiab cov uas tau phais qog.

Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.

Xov Tooj: 4008803716

Email：myimmnet@163.com